Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype.

By D. Sarrió, S. Rodríguez-Pinilla, D. Hardisson, A. Cano, G. Moreno-Bueno, J. Palacios. Cancer Research, 2008

1,091 citations recorded by the source corpus.

Epithelial-mesenchymal transition (EMT) is defined by the loss of epithelial characteristics and the acquisition of a mesenchymal phenotype. In carcinoma cells, EMT can be associated with increased aggressiveness, and invasive and metastatic potential. To assess the occurrence of EMT in human breast tumors, we conducted a tissue microarray-based immunohistochemical study in 479 invasive breast carcinomas and 12 carcinosarcomas using 28 different markers. Unsupervised hierarchical clustering of the tumors and statistical analysis showed that up-regulation of EMT markers (vimentin, smooth-muscle-actin, N-cadherin, and cadherin-11) and overexpression of proteins involved in extracellular matrix remodeling and invasion (SPARC, laminin, and fascin), together with reduction of characteristic epithelial markers (E-cadherin and cytokeratins), preferentially occur in breast tumors with the "basal-like phenotype." Moreover, most breast carcinosarcomas also had a basal-like phenotype and showed expression of mesenchymal markers in their sarcomatous and epithelial components. To assess whether basal-like cells have intrinsic phenotypic plasticity for mesenchymal transition, we performed in vitro studies with the MCF10A cell line. In response to low cell density, MCF10A cells suffer spontaneous morphologic and phenotypic EMT-like changes, including cytoskeleton reorganization, vimentin and Slug up-regulation, cadherin switching, and diffuse cytosolic relocalization of the catenins. Moreover, these phenotypic changes are associated with modifications in the global genetic differentiation program characteristic of the EMT process. In summary, our data indicate that in breast tumors, EMT likely occurs within a specific genetic context, the basal phenotype, and suggests that this proclivity to mesenchymal transition may be related to the high aggressiveness and the characteristic metastatic spread of these tumors.

Subfields: Cancer Research, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/78772a3004756260957104982a902f96b6242c1b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. R. Weinberg
2. M. Nieto
3. Lisa A. Carey
4. V. Raman
5. N. Ramirez
6. K. Polyak
7. X. Ye
8. F. Vesuna

In Oncology

1. R. Weinberg
2. M. Nieto
3. Jing Yang
4. X. Ye
5. K. Yeung
6. J. Tsai
7. S. Alahari
8. S. J. Serrano-Gomez

In Pulmonary and Respiratory Medicine

1. R. Weinberg
2. M. Nieto
3. X. Ye

Citations in the corpus

• Triple-negative breast cancer--current status and future directions. (2009, background): “BLBCs exhibit well-established characteristics of epithelial– mesenchymal transition, such as loss of epithelial characteristics and acquisition of a mesenchymal phenotype [14].”
• Epithelial–mesenchymal plasticity in carcinoma metastasis (2013, background): “In addition, immunohistochemical analysis of 28 molecular markers in 479 invasive breast carcinomas revealed clustering of EMT markers in tumors with a basal-like phenotype (Sarrio et al. 2008).”
• Interleukin-6 induces an epithelial–mesenchymal transition phenotype in human breast cancer cells (2009, background): “…evidence of epithelial–mesenchymal transition (EMT) phenotypes in human breast tumors (Heimann and Hellman, 2000; Moody et al., 2005; Cheng et al., 2008; Sarrio et al., 2008), few tumor microenvironmentderived extracellular cues capable of provoking this transition have been identified.”
• Epithelial Plasticity: A Common Theme in Embryonic and Cancer Cells (2013, background): “Partial EMTs are also observed in the epithelial component of carcinosarcomas (30) and at intermediate states during”
• Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications (2016, background): “Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, Jarrard DF, et al. Ecadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas.”
• Epithelial-Mesenchymal Plasticity: A central regulator of cancer progression (2015, background): “A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript metastatic dissemination (Huber et al., 2005; Morel et al., 2012; Rhim et al., 2012; Sarrio et al., 2008).”
• The basics of epithelial–mesenchymal transition (EMT): A study from a structure, dynamics, and functional perspective (2019, background): “…adhesion and increased motility, through which they cross barrier and migrates towards long distances owing to intense alternations in their cytoskeleton structural design (Sotiriou et al., 2003, Thiery & Lim, 2013; Kalluri & Weinberg, 2009; Mittal, 2018; Nieto, 2013; Sarrio et al., 2008).”
• Implications of the Hybrid Epithelial/Mesenchymal Phenotype in Metastasis (2015, background): “Importantly, among breast cancer subtypes, the ones with poor clinical outcomes – triple-negative (TNBC) and basal-like (BLBC) – are most enriched for such biphenotypic cells, indicating a strong association between aggressiveness and E/M phenotype (13,106,107).”
• Platform-independent and Label-free Quantitation of Proteomic Data Using MS1 Extracted Ion Chromatograms in Skyline (2012, background): “…implicated in the regulation of intermediate filament assembly (37), and because vimentin has been suggested to be a specific marker of a mesenchymal phenotype acquisition by tumor cells (38), measuring relevant phosphopeptides from vimentin may potentially increase sensitivity of this marker.”
• Triple-negative breast cancer: disease entity or title of convenience? (2010, background): “Some tumors with a basal-like phenotype might have acquired the basal-like characteristics through a process of transdifferentiation, called epithelial-to-mesenchymal transition (EMT)”
• EMT, the cytoskeleton, and cancer cell invasion (2009, background): “The actual occurrence of EMT in patients is still highly debated, yet with more detailed molecular and histopathological analysis and the advent of novel markers there is increasing evidence identifying EMT in various human cancers [19, 20].”
• The ins and outs of the epithelial to mesenchymal transition in health and disease. (2011, background): “EMT also correlates with invasiveness, a poor prognosis, and the most aggressive types of cancer such as the basal-type breast carcinomas (Sarrió et al. 2008).”
• Epithelial-Mesenchymal Transition in Cancer: Parallels Between Normal Development and Tumor Progression (2010, background): “Markers of EMT are preferentially displayed in the basal subtype as well as in a newly recognized claudin-low subtype, linking EMT with the molecular subtype of a tumor [74, 75].”